IMMP Immutep Limited
$0.37▲ +14.83%
Healthcare
Other
After hours
$0.35▼ -6.24%
Sep 11, 7:30 PM ET
Volume 3.10M
Avg Volume (10D) 447.7K
Key Metrics & Fundamentals
Market Cap
$55.01M
P/E Ratio
–
Div Yield
–%
52W Range
0.29 - 3.53
% vs 50 MA
-4.94%
% vs 200 MA
-70.30%
RSI-14
48.8
MACD Histogram
+0.0000
Beta (1Y vs SPY)
1.18
Free Cash Flow
-$40.43M
Gross Rev
–
Gross Profit
–
EBITDA
–
COGS
–
Operating Exp
–
Operating Income
–
EBIT
–
Pretax Income
–
Net Income
–
Price & Volume History
Loading chart…
Recent News
Immutep Outlines Focused Development Strategy for Eftilagimod Alfa (“efti”)
GlobeNewswire · Sep 11, 2026 12:00 PM
Immutep Quarterly Activities Report Q4 FY26
GlobeNewswire · Jul 30, 2026 12:00 PM
Immutep Announces Abstract Accepted for Presentation at the European Society for Medical Oncology (ESMO) Congress 2026
GlobeNewswire · Jul 24, 2026 12:00 PM
Correction: Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight
GlobeNewswire · Jul 21, 2026 5:00 PM
Immutep Granted New US Patent for Cancer Treatment Methods
MT Newswires · Jul 14, 2026 12:42 PM
Immutep Secures Fourth United States Patent for Eftilagimod Alfa in Combination with a PD-1 Pathway Inhibitor
GlobeNewswire · Jul 14, 2026 12:00 PM
Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight
GlobeNewswire · Jul 13, 2026 5:00 PM
Immutep Provides Clinical Update in 1st line NSCLC: Positive Mature Overall Survival Data from INSIGHT-003 and Update from TACTI-004
GlobeNewswire · Jul 13, 2026 12:00 PM
Immutep Shares Rise After Maxim Group Upgrade
MT Newswires · Jun 17, 2026 6:56 PM
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See IMMP's money flow as a full page
Social Sentiment
No Reddit posts found for IMMP.
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.